The role of proliferating stem‐like plasma cells in relapsed or refractory multiple myeloma: Insights from single‐cell RNA sequencing and proteomic analysis

Documenti analoghi

• Teclistamab for relapsed refractory multiple myeloma patients on dialysis
  di: P. Lebreton, et al.
  Pubblicazione: (2024)
• Dysplastic plasma cells in multiple myeloma
  di: Marco P. Barros Pinto
  Pubblicazione: (2025)
• Pembrolizumab and pralatrexate for relapsed or refractory peripheral T‐cell lymphomas
  di: Christina Poh, et al.
  Pubblicazione: (2026)
• T‐cell‐based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic
  di: S. Moraru, et al.
  Pubblicazione: (2025)
• Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM
  di: Iuliana Vaxman, et al.
  Pubblicazione: (2024)